Additional Advocacy Resources
The All Copays Count Coalition comprises more than 80 national 501c3 non-profit, non-partisan patient advocacy and provider organizations representing millions of people living with serious, complex, chronic illness.
Founded in 1934, the American College of Rheumatology is a non-profit, professional association committed to advancing the specialty of rheumatology.
Founded in 1847, the AMA works to inform lawmakers, guide decision-making and generate support for policies on critical issues that impact physicians, patients and the health care environment at both the national and state levels.
Mission Statement: To promote the science and practice of Rheumatology, foster the advancement and education of women in Rheumatology, and advocate access to the highest quality health care, and management of patients with Rheumatic diseases.
The Coalition of State Rheumatology Organizations is comprised of state and regional professional rheumatology societies whose mission is to advocate for excellence in the field of rheumatology, ensuring access to the highest quality care for the management of rheumatologic and musculoskeletal disease.
Founded in 1874, the Florida Medical Association is a professional association dedicated to the service and assistance of Doctors of Medicine and Doctors of Osteopathic Medicine in Florida.
The #KeepMyRx campaign seeks to raise public awareness about the benefits of medical stability and the impact on patient health of being forced by their health plans to switch medicines. The #KeepMyRx policy priorities include insurance reform that limits utilization management practices such as non-medical switching.
The National Organization of Rheumatology Management is a forum that promotes education, expertise and advocacy for rheumatology practices and their patients.
The Rheumatology Nurses Society is a professional organization committed to the development and education of nurses to benefit its members, patients, family and community.
The SAIM Coalition brings together national patient advocacy organizations, healthcare provider societies, and biopharmaceutical companies to develop state-based policy solutions to improve patient access to innovative medicines.